1-10 of 10
Mark W. Lowdell, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

Panagiotis Kottaridis, MD, PhD, Maria Tsirogianni, MD, Janet North, BSc, MSc, Chloe Marden, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath
Journal: Blood
Blood (2011) 118 (21): 946.
https://doi.org/10.1182/blood.V118.21.946.946
Published: 2011
Journal Articles

CMV-Reactive T Cells Can Be Isolated From G-CSF Mobilised Peripheral Blood Apheresates.

Edward R Samuel, MSc, Katy Newton, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath
Journal: Blood
Blood (2010) 116 (21): 1276.
https://doi.org/10.1182/blood.V116.21.1276.1276
Published: 2010
Journal Articles

CMV-Reactive γ/δ T Cells Are Equivalent to Their α/β Counterparts In the Lysis of CMV-Infected Targets – Potential for Post Transplant Adoptive Immunotherapy.

Andrea Knight, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath
Journal: Blood
Blood (2010) 116 (21): 1277.
https://doi.org/10.1182/blood.V116.21.1277.1277
Published: 2010
Journal Articles

Adoptive Transfer of CMV-Specific Donor T Cells Following Allogeneic Transplantation Leads to Rapid and Safe Systemic Reconstitution.

Karl S Peggs, MD, Kirsty Thomson, MD, Edward Samuel, BSc, MSc, Gemma Dyer, Julie Armoogum, Kwok Pang, BSc, MSc, Ronjon Chakraverty, MD, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath
Journal: Blood
Blood (2009) 114 (22): 44.
https://doi.org/10.1182/blood.V114.22.44.44
Published: 2009
Journal Articles

CMV-Reactive Gamma/Delta T Cells Expanded From CMV Seronegative Normal Healthy Individuals Lyse CMV-Infected Targets – Potential Adoptive Immunotherapy for Recipients of Stem Cell Transplants From CMV Seronegative Donors.

Andrea Knight, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath
Journal: Blood
Blood (2009) 114 (22): 2233.
https://doi.org/10.1182/blood.V114.22.2233.2233
Published: 2009
Journal Articles

A Phase I/II Clinical Trial of Tumour-Activated Allogeneic Natural Killer Cells in AML

Panos Kottaridis, Janet North, Ismail Bakhsh, Edward Samuel, Stephen Mackinnon, Mark W Lowdell, PhD, FRCPath
Journal: Blood
Blood (2008) 112 (11): 2901.
https://doi.org/10.1182/blood.V112.11.2901.2901
Published: 2008
Journal Articles

Tumor-Activated Human NK Cells Specificall Ylyse Autologous and Allogeneic NK-Resistant Tumor Targets.

Mark W. Lowdell, PhD, Ismail Bakhsh, MSc, Janet North, MSc, Chloe Marden, PhD, Elena Addison, MSc, Stephen Mackinnon, MD
Journal: Blood
Blood (2006) 108 (11): 3707.
https://doi.org/10.1182/blood.V108.11.3707.3707
Published: 2006
Journal Articles

Direct Isolation of Donor-Derived Antigen - Specific T Cells and Their Adoptive Transfer for Treatment or Prophylaxis of CMV Infection Following Allogeneic Transplantation.

Kirsty Thomson, MD, Moran Julie, BSc, Kwok Pang, MSc, Ed Samuel, BSc, Michael Desborough, BSc, Mark W. Lowdell, PhD, Stephen Mackinnon, MD
Journal: Blood
Blood (2006) 108 (11): 589.
https://doi.org/10.1182/blood.V108.11.589.589
Published: 2006
Journal Articles

CD69 Is Required for Activated NK Cell-Mediated Killing of Resistant Targets.

Chloe M. Marden, PhD, Janet North, MSc, Robert Anderson, PhD, Ismail A. Bakhsh, MSc, Elena Addison, MSc, Hannah Pittman, BSc, Stephen Mackinnon, MD FRCP FRCPath, Mark W. Lowdell, PhD MRCPath
Journal: Blood
Blood (2005) 106 (11): 3322.
https://doi.org/10.1182/blood.V106.11.3322.3322
Published: 2005
Journal Articles

Functional Helper T Cell Response to CMV Predicts Probability of CMV Vireamia Following Allogeneic Stem Cell Transplantation.

Hubertus C. Buyck, MBChB, Samantha J. Paston, BSc, Mark W. Lowdell, PhD, Stephen Mackinnon, MD, Vincent C. Emery, PhD
Journal: Blood
Blood (2004) 104 (11): 2224.
https://doi.org/10.1182/blood.V104.11.2224.2224
Published: 2004